BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/26/2020 12:01:04 PM | Browse: 659 | Download: 989
 |
Received |
|
2020-07-06 18:48 |
|
Peer-Review Started |
|
2020-07-06 18:49 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-07-30 17:54 |
|
Revised |
|
2020-08-13 06:55 |
|
Second Decision |
|
2020-09-14 11:04 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-09-14 19:48 |
|
Articles in Press |
|
2020-09-14 19:48 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-10-23 10:10 |
|
Publish the Manuscript Online |
|
2020-10-26 12:01 |
| ISSN |
1948-0210 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cell Biology |
| Manuscript Type |
Review |
| Article Title |
Mesenchymal stem cells as living anti-inflammatory therapy for COVID-19 related acute respiratory distress syndrome
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Feng Lin, Thomas E Ichim, Sandeep Pingle, Lawrence D Jones, Santosh Kesari and Shashaanka Ashili |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Feng Lin, PhD, Research Scientist, R and D, CureScience, No. 10225 Barnes Canyon Road #A207, San Diego, CA 92121, United States. flin@curescience.org |
| Key Words |
Mesenchymal stem cells; SARS-CoV-2; COVID-19; Cytokine storm; Acute respiratory distress syndrome; Immunomodulation |
| Core Tip |
Corona virus disease 2019 a disease caused by the severe acute respiratory syndrome coronavirus 2, and is growing exponentially, with no treatments currently available. Preclinical and clinical studies have shown that mesenchymal stem cells work in reversing acute respiratory distress syndrome caused by other conditions such as influenza virus infection, or sepsis. In this review we discuss the unique ability of mesenchymal stem cells, to act as a “living anti-inflammatory”, which can “rebalance” the cytokine/immune responses to restore equilibrium. |
| Publish Date |
2020-10-26 12:01 |
| Citation |
Lin F, Ichim TE, Pingle S, Jones LD, Kesari S, Ashili S. Mesenchymal stem cells as living anti-inflammatory therapy for COVID-19 related acute respiratory distress syndrome. World J Stem Cells 2020; 12(10): 1067-1079 |
| URL |
https://www.wjgnet.com/1948-0210/full/v12/i10/1067.htm |
| DOI |
https://dx.doi.org/10.4252/wjsc.v12.i10.1067 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
